Table 2.

Association among metastasis sites of mCRPC patients and periostin, integrin-α4, fibronectin expressions

		Periostin		Integrin-α4		Fibronectin
Metastasis sites	n	Mean	Median	Mean	Median	Mean	Median
Group 1:B	15	6.1 ± 2.83	6.32 (1.6–10.8)	0.9 ± 9.57	0.26 (0.01–2.7)	6.0 ± 3.43	7.0 (0.04–9.7)
Group 2: B + L	17	4.1 ± 2.25	3.5 (0.88–9.9)	1.4 ± 2.21	0.22 (0.03–7.4)	6.2 ± 4.5	5.8 (0.01–12.5)
Group 3: B + L + O	8	4.7 ± 2.46	4.6 (2–9.7)	2.7 ± 2.76	2.0 (0.03–7.6)	8.8 ± 2.7	8.3 (5.1–14.1)
Statistics		P		P		P
Group1 vs. Group2		0.040*		0.650		0.821
Group1 vs. Group3		0.208		0.100		0.093
Group2 vs. Group3		0.641		0.308		0.294
Group1 vs. Group(2 + 3)		0.039*		0.295		0.371
Group(1 + 2) vs.Group3		0.697		0.146		0.144

B: bone; L: lymph; O: organ; mCRPC: metastatic castration-resistant prostate cancer.

^*P < 0.05.